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Abstract
Introduction Cellular metabolism is altered during cancer
initiation and progression, which allows cancer cells to
increase anabolic synthesis, avoid apoptosis and adapt to
low nutrient and oxygen availability. The metabolic nature
of cancer enables patient cancer status to be monitored by
metabolomics and lipidomics. Additionally, monitoring
metabolic status of patients or biological models can be
used to greater understand the action of anticancer
therapeutics.
Objectives Discuss how metabolomics and lipidomics can
be used to (i) identify metabolic biomarkers of cancer and
(ii) understand the mechanism-of-action of anticancer
therapies. Discuss considerations that can maximize the
clinical value of metabolic cancer biomarkers including
case–control, prognostic and longitudinal study designs.
Methods A literature search of the current relevant primary
research was performed.
Results Metabolomics and lipidomics can identify meta-
bolic signatures that associate with cancer diagnosis,
prognosis and disease progression. Discriminatory
metabolites were most commonly linked to lipid or energy
metabolism. Case–control studies outnumbered prognostic
and longitudinal approaches. Prognostic studies were able
to correlate metabolic features with future cancer risk,
whereas longitudinal studies were most effective for
studying cancer progression. Metabolomics and lipidomics
can help to understand the mechanism-of-action of anti-
cancer therapeutics and mechanisms of drug resistance.
Conclusion Metabolomics and lipidomics can be used to
identify biomarkers associated with cancer and to better
understand anticancer therapies.
Keywords Mass spectrometry  Nuclear magnetic
resonance  Leukemia  Stratified medicine  Nutraceutical 
Drug redeployment
1 Introduction: cancer metabolism
Cancer initiation and progression is associated with specific
changes to cellular metabolism that are not simply by-
products of the disease; instead they appear to drive the
disease (Boroughs and DeBerardinis 2015; Wishart 2015).
Activated oncoproteins alter cell metabolism (Kimmelman
2015; Sancho et al. 2015) and some metabolic enzymes are
now being considered as oncoproteins (Migita et al. 2009).
At the genetic level cancer is very complex and heteroge-
neous (Lohr et al. 2014), however at the metabolic level only
a few processes are altered (Wishart 2015). The identifica-
tion and measurement of cancer-specific metabolic and lipid
markers from low-invasive patient samples has the potential
to monitor prognosis and disease in cancer patients.
For metabolic or lipid markers to be robust indicators of
cancer they need to be anchored in biochemical knowledge
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of tumour metabolism (Fig. 1). High glucose demand and
aerobic glycolysis are common metabolic traits of cancer
cells (Vander Heiden et al. (2009); Warburg 1956). This is
often accompanied by mutagenic disruption to TCA cycle
enzymes (King et al. 2006), creating a metabolic phenotype
that directs glucose carbon towards anabolic synthesis
(Boroughs and DeBerardinis 2015). Additionally, this
favours NADPH recycling to maintain glutathione levels
and an optimal cellular redox status (Patra and Hay 2014)
(Fig. 1). Functional mitochondria are essential to cancer
cells with TCA cycle disruption (Wallace 2012). Mito-
chondria contribute towards anabolic biosynthesis in
tumours (Ahn and Metallo 2015), including de novo fatty
acid biosynthesis—a process that is upregulated in several
cancers (Currie et al. 2013). Glutaminolysis is a key
metabolic process in MYC driven cancers whereby carbon
from the catabolism of glutamine is imported into the
mitochondria to maintain mitochondrial membrane poten-
tial (Wise and Thompson 2010). Carbon from glutamine is
also used for the anabolic synthesis of proteins and
nucleotides (DeBerardinis et al. 2007). Additionally, the
local tumour environment plays a key role in the metabo-
lism of cancer cells. Here, nutrient- and oxygen-poor
tumour cells scavenge alternate carbon sources—lactate
(Doherty and Cleveland 2013), acetate (Kamphorst et al.
2014; Schug et al. 2015) and lipids (Kamphorst et al.
2013)—to maintain energy production and anabolic
synthesis.
This review will discuss considerations required for
metabolic monitoring of cancer patients in the clinic.
Current examples of its application to monitor disease risk
and incidence, disease staging and understand the mecha-
nism-of-action of anticancer therapeutics [pharma-
cometabolomics (Kaddurah-Daouk et al. 2008; Lindon
et al. 2006)] will be discussed.
2 Metabolomic and lipidomic strategies
2.1 Sample types
The identification of metabolic markers that can clinically
monitor cancer status requires access to patient samples
(Mayers et al. 2014). Analysis of tissue samples provides
mechanistic understanding of cancer (Ren et al. 2016;
Rocha et al. 2015; Wang et al. 2013), however such
invasive samples are less suited for regular patient moni-
toring. An exception is magnetic resonance imaging (MRI)
where metabolic profiles of tumour tissue can be non-in-
vasively obtained (Gill et al. 2014). Low-invasive patient
samples (e.g. serum, urine) are ideal for regular patient
monitoring as they offer minimal patient discomfort and
can justifiably be taken from healthy (control) patients. The
location of the cancer may influence the chosen sample
type, e.g. urine for bladder cancer (Jin et al. 2014), breath
for lung cancer (Li et al. 2015). Low invasive samples are
generally extracellular fluids. Here, the metabolic profile is
dependent on cellular uptake and excretion from all bodily
processes (not just the cancer), which must be considered
during data interpretation. Pharmacometabolomics analysis
to understand the mechanism-of-action of anticancer ther-
apeutics often begins in cell lines (Southam et al. 2015),
before progressing to ex vivo studies (Koczula et al. 2016)
and then patient samples (Schuler et al. 2015).
2.2 Analytical approaches
The study of cancer metabolism is most typically done by
steady-state metabolomics or lipidomics using liquid
chromatography-mass spectrometry (LC–MS) (Mayers
et al. 2014; Kuhn et al. 2016; Piszcz et al. 2016), gas
chromatography-MS (GC–MS) (Xie et al. 2015; Wittmann
et al. 2014), direct infusion MS (DIMS) (Southam et al.
2015; Li et al. 2013; Southam et al. 2007) or nuclear
magnetic resonance (NMR) spectroscopy (Fages et al.
2015; Lodi et al. 2013). To retain spatial information,
metabolic imaging approaches can be used [e.g. matrix-
assisted laser desorption/ionization MS (Krasny et al.
2015)]. Analytical techniques more suited to the clinical
setting are emerging, including liquid extraction surface
analysis (LESA) MS to profile lipids directly from dried
Fig. 1 A simplified overview of metabolic changes that occur in
cancer. Cancers often exhibit increased aerobic glycolysis resulting in
glucose carbon being directed towards lactate and the anabolic
synthesis of nucleotides, amino acids and lipids. This is associated
with disruption of the TCA cycle and the increased use of glutamine
as a carbon source (glutaminolysis). Cancer-induced increase of the
pentose phosphate pathway can increase NADPH recycling to protect
cells against oxidative stress
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blood spots (Griffiths et al. 2015); portable hand-held
Raman spectrometery (Mabbott et al. 2013); and rapid
evaporative mass spectrometry (Schaefer et al. 2009). The
intelligent knife (iKnife) where a surgical scalpel is cou-
pled to a MS detector to measure intraoperative real-time
lipidomics capable of distinguishing tumour tissue from
healthy tissue is an example for the latter (Balog et al.
2013).
2.3 Stable isotopic labelling analysis
Stable isotope-labelled compounds (that contain 13C, 2H,
15N atoms; most commonly 13C-glucose and 13C-glu-
tamine) can be traced into metabolites and lipids using MS
or NMR metabolomics and lipidomics. This provides
dynamic pathway information, which can inform on cancer
processes (Kamphorst et al. 2013) and the mechanism-of-
action of anticancer drugs (Southam et al. 2015). The non-
toxic nature of stable isotopes enables their use in patients,
including to demonstrate the heterogeneous metabolic
nature of lung cancers (Hensley et al. 2016). Furthermore,
stable-isotope labelling combined with hyperpolarized
MRI metabolomic imaging can monitor cancer stages and
therapy response in vivo by measuring the conversion of
hyperpolarized 13C glucose or 13C-pyruvate to 13C-lactate
in tumours (Rodrigues et al. 2014; Saito et al. 2015). The
large concentration differences of lactate between tumour
and healthy tissue allow for more sensitive and precise
tumour detection than 18fluoro-2-deoxyglucose positron
emission tomography (18FDG-PET) where tumour and
surrounding tissue 18FDG levels can sometimes show poor
contrast (Rodrigues et al. 2014).
3 Identification of metabolic cancer biomarkers
3.1 Maximising the clinical value of metabolic
cancer biomarkers
Several metabolic markers have been associated with
cancer status (Table 1), however this information is yet to
be used for routine cancer screening in the clinic. To ensure
future success of metabolic biomarkers in cancer patients
certain aspects must be considered. Biomarkers should be
more informative, less invasive and/or cheaper than current
approaches (e.g. histology). To identify specific metabolic
biomarkers of cancer, patient-to-patient variation—in-
cluding ethnicity, sex, nutritional status, general health—
should be minimised. The sampling procedure must be
technically reproducible and the study size large enough to
provide adequate statistical power. Different genetic
mutations create subtle differences in metabolism, for
instance RAS transformation will increase cellular glucose
uptake and use in anabolic processes (Boroughs and
DeBerardinis 2015). Therefore, genetic phenotyping of
patient cancers [e.g. RAS status (Bertini et al. 2012)] would
aid data interpretation and allow biomarkers to be assigned
to specific mutations. Spectral features identified as
biomarkers should be fully annotated and anchored in a
sound biochemical understanding of cancer. This includes
distinguishing metabolic cancer traits from general whole
body metabolism and the metabolism of therapeutic drugs.
Collections or ‘panels’ of markers are generally favoured
over single biomarkers (Zang et al. 2014) as they better
describe multifactorial metabolic processes. Furthermore,
to overcome inter-patient variation of baseline metabolite
levels, biomarkers can be measured as ratios of
pairs/groups of compounds rather absolute intensity mea-
surements of individual compounds (Zeng et al. 2015).
Effective study design is important (Fig. 2). Case–con-
trol studies compare a cohort of cancer patients against a
cohort of healthy patients to identify metabolic markers of
disease (Xie et al. 2015). Prognostic case–control studies
analyse patient samples taken before cancer diagnosis to
identify metabolic signatures that are indicative of cancer
risk (Mayers et al. 2014). Longitudinal studies take several
samples from patients over a time period—e.g. prior to
diagnosis, at diagnosis and in remission—meaning each
patient has a control sample to which other sample time-
points are compared. Longitudinal studies can be used to
identify metabolic markers indicative of (i) cancer prog-
nosis and risk of disease (Cook et al. 2016), (ii) patient
remission or relapse (Lodi et al. 2013) and (iii) the
mechanism-of-action and success of anticancer drug ther-
apies (Jobard et al. 2015).
3.2 Case–control studies to identify metabolic
markers of cancer
Case–control study design is the most commonly used
approach to identify metabolic markers associated with
cancer (Armitage and Barbas 2014) (Fig. 2). Many of these
biomarkers are related to lipid metabolism (Table 1). Free
fatty acids and lysophosphatidylcholines were shown to be
elevated in serum from lung (Li et al. 2014) and colorectal
cancer (Li et al. 2013) patients compared to controls, whilst
phospholipid composition was altered in the serum of
patients with breast (Yang et al. 2015), colorectal (Li et al.
2013) and ovarian (Buas et al. 2016) cancers. These
changes are consistent with the lipogenic phenotype asso-
ciated with cancer (Menendez and Lupu 2007) and cancer-
induced changes to phospholipid composition (Marien
et al. 2015). Other lipid changes include increased serum
acetylcarnitine and acylcarnitine levels in aggressive
chronic lymphocytic leukaemia (CLL) patients relative to
indolent CLL patients (Piszcz et al. 2016), and increased
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carnitine and select acylcarnitines in urine from bladder
cancer patients (Jin et al. 2014). This suggests an alteration
of mitochondrial fatty acid b-oxidation, which has been
shown as an anticancer target (Samudio et al. 2010). Non-
lipid metabolic markers of cancer mainly included gly-
colytic or TCA cycle metabolites (An et al. 2015; Jin et al.
2014; Wittmann et al. 2014). Alanine was identified as a
marker in three studies: elevated in gastric cancer (Chan
et al. 2016) and leptomeningeal carcinomatosis (An et al.
2015), and decreased in ovarian cancer (Buas et al. 2016).
Changeable alanine levels may be related to the glycolytic
cancer phenotype where pyruvate can be used to produce
alanine and other non-essential amino acids (Munoz-
Pinedo et al. 2012).
3.3 Prognostic case–control and longitudinal
approaches to identify metabolic markers
associated with the risk of developing cancer
With the correct study design, metabolomics and lipi-
domics can identify metabolic markers that are indicative
of future cancer risk. This could allow patients to be treated
earlier or enable the design of interventions that delay or
prevent cancer onset. For this approach, biological samples
are taken from multiple patients without cancer—repre-
senting pre-disease baseline metabolism. Patients are then
monitored over months/years for incidence of cancer. A
prognostic case–control study compares metabolic baseline
profiles from individuals who develop cancer against
matched control patients who do not develop cancer
(Fig. 2; Table 1) (Kuhn et al. 2016; Mayers et al. 2014). A
prognostic longitudinal approach requires further sampling
from each subject (e.g. on diagnosis, in remission; Fig. 2),
which can then be compared to baseline metabolism (Cook
et al. 2016). The collection of baseline samples before
cancer diagnosis requires years of forward planning or
access to archived patient samples. Also, an initial large
patient cohort is required to ensure sufficient patients will
develop cancer—often several thousand subjects (Kuhn
et al. 2016; Mayers et al. 2014). As a result, prognostic
studies are less common to standard case–control studies.
However, this approach has shown that metabolic markers
can indicate cancer risk years before diagnosis (Kuhn et al.
2016), demonstrating it to be clinically very powerful.
Recent prognostic case–control metabolomics studies
indicate that blood lipid composition is indicative of future
cancer risk (Table 1). Serum levels of lysophosphatidyl-
cholines, particularly LPC(18:0), are negatively associated
with breast, prostate and colorectal cancer risk, whereas the
phosphatidylcholine(30:0) level was positively associated
(Kuhn et al. 2016). A separate study showed that many
serum lipids—including free fatty acids and various
phospholipids—have a negative association with
aggressive prostate cancer (Mondul et al. 2015). A further
study showed that levels of unsaturated lipids in the serum
were negatively associated with hepatocellular carcinoma
incidence (Fages et al. 2015). This demonstrates the
importance of lipid metabolism in cancer and is consistent
with findings from case–control studies (above). Consid-
ering non-lipid prognostic markers (Table 1), altered serum
levels of energy-related metabolites were associated with
cancer: a-ketoglutarate and citrate were negatively asso-
ciated with prostate cancer (Mondul et al. 2015) and glu-
cose positively associated with hepatocellular carcinoma
(Fages et al. 2015). Elevated serum levels of branched-
chain amino acids are associated with a[twofold increased
risk of pancreatic ductal adenocarcinoma (Mayers et al.
2014), which is in contrast to hepatocellular carcinoma
where the opposite was reported (Fages et al. 2015). The
inconsistency may be explained by the effect the cancer has
on the function of the disease tissue—in pancreatic ductal
adenocarcinoma, altered pancreas function changes glu-
cose metabolism leading to whole-body protein breakdown
and elevated branched chain amino acids (Mayers et al.
2014). This emphasises the need to consider all bodily
processes when interpreting data acquired from patient
biofluids.
Currently, the application of longitudinal metabolomics
to monitor cancer prognosis is rare. However, this approach
has been used to analyse mouse urine and can successfully
predict the incidence of several different types of cancer
(Cook et al. 2016). A notable advantage of a longitudinal
approach over a prognostic case–control approach is the
analysis of metabolism both before diagnosis and on
diagnosis. This establishes metabolic indicators of cancer
risk while also understanding how and why these metabolic
processes change on cancer initiation.
3.4 Identification of metabolic markers of cancer
progression, relapse and remission
Longitudinal metabolomics is ideal to monitor cancer
progression, relapse and remission. Here, patient samples
are collected at cancer diagnosis and on several occasions
afterwards (Fig. 2). Analysis of the samples aims to iden-
tify metabolic features that correlate with—and can
therefore be indicative of—relapse or remission (Table 1).
Longitudinal studies have shown TCA cycle intermediates
and RNA degradation products to decrease in colorectal
cancer patients’ serum once remission or stable disease has
been reached (Zhu et al. 2015). Serum levels of carnitine
and acetylcarnitine were lower in remission and increased
in relapse in multiple myeloma patients (Lodi et al. 2013).
This indicates that mitochondrial b-oxidation is altered at
different cancer stages, which is consistent with case–
control studies above (Jin et al. 2014; Piszcz et al. 2016).
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Case–control metabolomics has also been applied to
greater understand cancer progression including a study
where aromatic amino acid levels in patient urine samples
were shown to be indicative of bladder cancer disease stage
(Alberice et al. 2013).
A key consideration when investigating cancer pro-
gression is the distinction between drug-induced metabolic
changes—as cancer patients will likely receive therapy on
diagnosis—and cancer-induced metabolic changes. This
issue is highlighted in a multiple myeloma study where the
biomarkers that were able to distinguish patients in
remission from those at diagnosis (glucose, citrate and
lactate) were likely attributable to bortezomib drug therapy
(Puchades-Carrasco et al. 2013). The value of these
markers as indicators of disease remission is unclear
without an understanding of the therapeutic drug
metabolism.
4 Using metabolomics and lipidomics
to understand the mechanism-of-action
of anticancer therapeutics
Metabolomics and lipidomics can be used to elucidate the
metabolic mechanism-of-action of anticancer therapeutics.
This information has the potential to improve therapies and
understand why some patients respond but others do not
(Nicholson et al. 2011; Holmes et al. 2015). The following
sections highlight how metabolomics and lipidomics con-
tribute to understanding drug action—including optimising
drug delivery strategies, understanding drug resistance and
exploration of nutraceuticals for anticancer therapy.
4.1 Anticancer therapeutics
Metabolomic and lipidomic investigation of anticancer
therapeutics has been applied to patient samples and
in vitro models (He et al. 2015; Schuler et al. 2015). The
most commonly studied drug is metformin, which was
originally intended to treat type II diabetes but also has
anticancer activity arising from its inhibition of mito-
chondrial complex I and production of energetic stress
(Pernicova and Korbonits 2014). Metabolomics analysis of
serum samples from metformin-treated breast cancer
patients revealed disruptions to glucose and insulin meta-
bolism (Lord et al. 2015). Further metabolomics analyses
indicated that metformin also alters methionine and folate
cycles to decrease nucleotide synthesis, which may further
contribute to the anticancer activity (Jara and Lo´pez-
Mun˜oz 2015). Additional examples of metabolomic and
lipidomic investigation of anticancer therapeutics are
detailed in Table 2.
4.2 Drug redeployment
Drug redeployment (also known as drug repositioning or
drug repurposing) involves the use of existing drug(s) in a
situation it was not originally intended (Ashburn and Thor
2004). Candidate drugs would typically be identified by
screening a panel of licenced drugs for anticancer effect.
The benefit of this approach is that drug pharmacokinetics
and toxicity are already known, eliminating the need for
early stage clinical trials. However, the exact anticancer
mechanism of the drug is often unknown. Metabolomics
and lipidomics has been used to understand the metabolic
mechanism-of-action of redeployed anticancer drugs, e.g.
metformin (see above), aspirin (Liesenfeld et al. 2016) and
bezafibrate/medroxyprogesterone acetate (Southam et al.
2015) (Table 2). There are, however, important consider-
ations when using metabolomics and lipidomics to eluci-
date drug mechanism. Firstly, it can be challenging to
distinguish anticancer metabolic effects of the drug from
the whole body metabolic response to the drug. In this case,
further experimentation is required to prove that the
metabolic changes actually correlate to anticancer effect.
Additionally, redeployed drugs are often used as combi-
nations and different doses compared to their original
intended prescribed dose (Khanim et al. 2009). This could
alter drug effects and/or increase the number of metabolic
processes that are perturbed, making it more difficult to
distinguish anticancer metabolic effects from the general
metabolic perturbations caused by the drugs.
4.3 Stratified and personalised medicine
Stratified medicine aims to predict whether cancer patients
will respond to therapy (Trusheim et al. 2007). Using a
prognostic study design (Fig. 2b—where the outcome is
drug response rather than cancer incidence) it is possible to
identify metabolic profiles predictive of drug response,
which could be used to personalise treatments for indi-
vidual patients (Nicholson et al. 2011). Adopting this
approach, metabolomics has been utilised to understand
how mitomycin C should be used in the treatment of
pancreatic cancer (Navarrete et al. 2014). In this study,
patient pancreatic adenocarcinoma cells were xenografted
on to a murine tumour model and then cells were treated
with mitomycin C, rapamycin or a combination of both.
Mitomycin C had a greater anticancer effect than rapa-
mycin alone or the combined drugs. The authors propose
that the effectiveness of mitomycin C alone was due to its
effect on central carbon metabolism. Metabolomics has
also been used to stratify metformin treatment. It was
shown that cells with mutated isocitrate dehydrogenase 1
(IDH1) have a metabolic phenotype that increases their
vulnerability to metformin (Cuya`s et al. 2015). This
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suggests that metformin would be most effective against
tumours with IDH1 mutations [e.g. brain tumours and acute
myeloid leukaemia (Balss et al. 2008; Schnittger et al.
2010].
4.4 Novel drug administration strategies
Advancements in drug administration can allow drugs to
reach the target cancer tissue more effectively, e.g. poly-
mer-nanoparticle-encapsulation can co-deliver two drugs—
doxorubicin and paclitaxel—to cancer cells to maximise
the synergistic effect of the drugs (Wang et al. 2011). NMR
metabolomics has been used to investigate systemic toxic
effect(s) of the polymer-nanoparticle-encapsulation mate-
rial used to deliver doxorubicin and paclitaxel compared to
the free forms of the drugs in mice (Song et al. 2015). The
encapsulation material induced a slight and temporalT
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Fig. 2 Metabolomics and lipidomics study designs. a Case–control
studies utilise genetically different cohorts for control subjects and
subjects with cancer. b Prognostic case–control studies use samples
taken from patients before an event, e.g. cancer diagnosis. This
enables metabolic features to be correlated with future cancer risk.
c Longitudinal approaches analyse samples taken from each patient at
multiple time-points
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metabolic effect in the mice—supporting this as a low
toxicity approach—while encapsulation decreased the
toxicity of the drugs on the heart compared to adminis-
tration of free drugs (Song et al. 2015).
4.5 Drug resistance
Cancer cells often develop resistance towards drug thera-
pies (Gottesman 2002). Understanding why resistance
occurs could allow the therapy to be modified to overcome
the resistance. Metabolomics has informed on the resis-
tance mechanism of some anticancer drugs. Resistance to
the chemotherapeutic agent temozolomide is common
during the treatment of glioblastoma multiforme (St-Coeur
et al. 2015). Metabolomics has been used to understand the
mechanism of resistance in glioblastoma multiforme cell
lines and primary tumours, and also to explore the meta-
bolic effects of the temozolomide-sensitizing agent,
Lomeguatrib (St-Coeur et al. 2015). Glucose, citrate and
isocitrate were increased in resistant cells, whereas alanine,
choline, creatine and phosphorylcholine were increased in
sensitive cells, demonstrating a metabolic aspect to the
drug resistance (St-Coeur et al. 2015). These metabolic
signatures could predict drug responses and, once the
metabolic perturbations are understood, could help con-
tribute to the improvement of therapies in glioblastoma
multiforme. Additionally, the imaging approach, time-of-
flight secondary ion mass spectrometry (ToF–SIMS), has
been used to study metabolic regulation of hypoxia-in-
duced chemoresistance to doxorubicin treatment of multi-
cellular tumour spheroids (Kotze et al. 2013). Cholesterol
and diacylglycerols were implicated as response markers of
treatment in the hypoxic regions, which suggested that
lipids play a role in drug response and resistance in hypoxic
regions of tumours (Kotze et al. 2013).
4.6 Nutraceutical cancer treatments
Natural plant extracts or plant-derived nutrients can have
anticancer properties (Babbar et al. 2015), and therefore
often offer a viable alternative to pharmaceuticals. Meta-
bolomics and lipidomics can aid with the elucidation of the
mechanism-of-action of such compounds. Volatile oil
extracted from Saussurea lappa Decne in addition to cos-
tunolide and dehydrocostus lactone isolated from the oil
have shown anticancer properties against breast cancer
cells (Peng et al. 2015). Metabolomics of serum and urine
samples from MCF-7 xenograft mice revealed that the oil
and the extracted compounds can reverse the metabolic
phenotype associated with the MCF-7 xenograft (initial
MCF-7 xenograft increases glycolysis and steroid hormone
metabolism, and decreases unsaturated fatty acid metabo-
lism) (Peng et al. 2015). Halofuginone, extracted from
Dichroa febrifuga, can inhibit colorectal cancer growth
in vitro and in vivo (Chen et al. 2015). Metabolic flux
analysis showed halofuginone to decrease glycolytic and
TCA cycle intermediates, which was correlated with
reduced GLUT 1 activity and glucose uptake (Chen et al.
2015). Lipidomics revealed a decrease in phospholipids,
ceramide and sphingomyelin after treatment, which was
consistent with the reported halofuginone-induced decrease
of fatty acid synthase expression (Chen et al. 2015). These
findings suggest that halofuginone can target the known
metabolic cancer targets aerobic glycolysis and fatty acid
biosynthesis. Flexibilide isolated from coral (Sinularia
flexibilis) has anticancer properties (Gao et al. 2016).
Metabolomics analysis of flexibilide-treated HCT-116
colorectal cancer cells indicated that the compound mod-
ulates sphingolipid metabolism, amino acid metabolism,
phospholipid metabolism and pyrimidine metabolism,
which the authors suggest may be associated with the anti-
tumour activity (Gao et al. 2016). Nutmeg has also been
studied for its effect against colorectal carcinoma (Li et al.
2015a). Serum metabolomics revealed that colon cancer
bearing mice have elevated levels of uremic toxins cresol
sulfate, cresol glucuronide, indoxyl sulfate and phenyl
sulfate, which are likely generated from gut microbiota and
are implicated in tumorigenesis (Li et al. 2015a). Nutmeg
has been shown to attenuate the serum levels of these
compounds, potentially reflecting the antibacterial and
anticancer properties of nutmeg (Li et al. 2015a). This
study highlights that it is important to understand the role
of gut microbiota in cancer—an expanding and important
research topic. It has been shown that human colorectal
cancer cells carrying KRAS and BRAF mutations—giving
them a highly glycolytic phenotype—can be selectively
killed by high doses of vitamin C (Yun et al. 2015).
Metabolomics revealed that vitamin C causes pentose
phosphate pathway metabolites and glycolytic intermedi-
ates located up-stream of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) to increase in KRAS and BRAF
mutated colorectal cancer cells, whereas metabolites down-
stream of GAPDH were decreased (Yun et al. 2015).
Vitamin C was subsequently demonstrated to inhibit the
GAPDH enzyme through the accumulation of reactive
oxygen species (Yun et al. 2015).
5 Conclusions and future perspectives
Metabolomics and lipidomics are important tools for can-
cer research. They can be used to discover biomarkers
indicative of patient prognosis, diagnosis and treatment
efficacy, and to aid in the elucidation of the mechanism-of-
action of novel and existing anticancer therapeutics. To
identify robust and clinically useful biomarkers effective
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study design is essential. Prognostic studies—where sam-
ples are taken prior to cancer diagnosis—can identify
metabolic markers indicative of future cancer risk. Longi-
tudinal studies—involving analysis of multiple samples
taken the each patient over a time period—is a good
strategy to investigate the metabolic aspects of cancer
progression. Considering anticancer therapy development,
metabolomics and lipidomics have contributed to the
development and understanding of pharmaceutical thera-
pies, nutraceutical therapies and novel drug delivery
strategies. Key future research applications for metabo-
lomics and lipidomics are to investigate the role of gut
microbiota in cancer and to better understand how meta-
bolic therapies can be tailored using a stratified medicine
approach. Understanding gut microbiota in cancer is par-
ticularly important given that this can alter the metabolic
response to drug therapies (Li et al. 2015b) and also the
efficacy anticancer treatment (Ve´tizou et al. 2015).
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